ARCLIZON Trademark Information

Trademark by Regeneron Pharmaceuticals, Inc.

Pharmaceutical preparations and substances for the treatment of immunological diseases and disorders, heart and circulatory diseases, hypertension, cardiovascular diseases, urological diseases, gastrointestinal disorders, metabolic diseases, chronic peripheral arterial occlusive diseases, inflammatory diseases and disorders

Classification Information

Intent to Use Trademark - Applicant has not submitted proof of use in commerce the the USPTO.

Primary Class: Class Details:
Class (005)
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
First Use Anywhere:: Not provided
First Use In Commerce: Not provided
General Information
Word mark: ARCLIZON
Status/Status Date:
ABANDONED - NO STATEMENT OF USE FILED
6/14/2010
Serial Number: 78914040
Filing Date: 6/22/2006
Registration Number: NOT AVAILABLE
Registration Date: NOT AVAILABLE
Goods and Services: Pharmaceutical preparations and substances for the treatment of immunological diseases and disorders, heart and circulatory diseases, hypertension, cardiovascular diseases, urological diseases, gastrointestinal disorders, metabolic diseases, chronic peripheral arterial occlusive diseases, inflammatory diseases and disorders
Mark Description: NOT AVAILABLE
Type Of Mark: TradeMark
Published For Opposition Date: 2/20/2007
Last Applicant/Owner:
Regeneron Pharmaceuticals, Inc.
Tarrytown, NY 10591
Mark Drawing Code: Standard Character Mark
Design Search:
(NO DATA)
Register Type: Principal
Disclaimer: (NOT AVAILABLE)
Correspondent:
OHLANDT, GREELEY, RUGGIERO & PERLE, LLP
1 LANDMARK SQ FL 10
STAMFORD CT 06901-2619
Current Status:
ABANDONED - NO STATEMENT OF USE FILED
6/14/2010
Correspondent Search:
Terrence J. McAllister is a correspondent of ARCLIZON trademark.
Current Overall Rating:
RatingRatingRatingRatingRating

(0 review)

As seen on